LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

Vertex Pharmaceuticals Inc

Slēgts

SektorsVeselības aprūpe

438.4 0.96

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

429

Max

438.62

Galvenie mērījumi

By Trading Economics

Ienākumi

-267M

646M

Pārdošana

-142M

2.8B

P/E

Sektora vidējais

30.42

56.602

EPS

4.06

Peļņas marža

23.33

Darbinieki

6,100

EBITDA

-556M

630M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+18.09% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 31. jūl.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-6.9B

113B

Iepriekšējā atvēršanas cena

437.44

Iepriekšējā slēgšanas cena

438.4

Ziņu noskaņojums

By Acuity

51%

49%

314 / 382 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

Vertex Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 5. maijs 21:00 UTC

Peļņas

Vertex Pharmaceuticals 1Q Sales Rise, Profit Falls on Impairment Charge

2025. g. 10. febr. 22:11 UTC

Peļņas

Vertex Pharmaceuticals Posts Higher 4Q Revenue

2025. g. 31. janv. 00:19 UTC

Galvenie tirgus virzītāji

Vertex Pharmaceuticals Shares Gain After FDA Approves Non-Opioid Pain Drug

2024. g. 19. dec. 12:25 UTC

Galvenie tirgus virzītāji

Vertex Pharmaceuticals Shares Drop on Mixed Results in Drug Trial

2024. g. 4. nov. 21:44 UTC

Peļņas

Vertex Pharmaceuticals Raises Full-Year Outlook After 3Q Earnings

2025. g. 6. maijs 16:31 UTC

Peļņas

Vertex Pharmaceuticals Stock Is Tumbling After Earnings. Here's Why. -- Barrons.com

2025. g. 5. maijs 20:03 UTC

Peļņas

Vertex Pharmaceuticals Sees 2025 Rev $11.85B-$12B >VRTX

2025. g. 5. maijs 20:01 UTC

Peļņas

Vertex Pharmaceuticals 1Q Net $646.3M >VRTX

2025. g. 5. maijs 20:01 UTC

Peļņas

Vertex Pharmaceuticals 1Q Rev $2.77B >VRTX

2025. g. 5. maijs 20:01 UTC

Peļņas

Vertex Pharmaceuticals 1Q EPS $2.49 >VRTX

2025. g. 5. maijs 20:01 UTC

Peļņas

Vertex Pharmaceuticals 1Q Adj EPS $4.06 >VRTX

2025. g. 27. apr. 11:00 UTC

Top Ziņas

Wall Street's New Tariff Safe Haven: High-Tax Biotech Stocks -- Heard on the Street -- WSJ

2025. g. 11. apr. 09:30 UTC

Top Ziņas

How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs -- Heard on the Street -- WSJ

2025. g. 28. febr. 12:00 UTC

Top Ziņas

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

2025. g. 11. febr. 21:12 UTC

Peļņas

Vertex Posts 'Another Impressive Quarterly Revenue Beat.' But The Future Remains Uncertain. -- IBD

2025. g. 11. febr. 14:21 UTC

Peļņas

Vertex Posts 'Another Impressive Quarterly Revenue Beat.' But The Future Remains Uncertain. -- IBD

2025. g. 10. febr. 21:12 UTC

Peļņas

Vertex Pharmaceuticals: Duncan McKechnie, Current Head of N Amer Comml, to Assume Role of Chief Comml Officer

2025. g. 10. febr. 21:12 UTC

Peļņas

Vertex Pharmaceuticals CFO Charlie Wagner to Assume Additional Role of COO

2025. g. 10. febr. 21:11 UTC

Peļņas

Vertex Pharmaceuticals COO Stuart Arbuckle Plans to Retire July 1

2025. g. 10. febr. 21:04 UTC

Peļņas

Vertex Pharmaceuticals Sees Combined Non-GAAP R&D, AIPR&D and SG&A Expenses $4.9B to $5.0 B >VRTX

2025. g. 10. febr. 21:04 UTC

Peļņas

Vertex Pharmaceuticals Sees Combined GAAP R&D, AIPR&D and SG&A Expenses $5.55B to $5.7 B >VRTX

2025. g. 10. febr. 21:02 UTC

Peļņas

Vertex Pharmaceuticals Sees 2025 Rev $11.75B-$12B >VRTX

2025. g. 10. febr. 21:01 UTC

Peļņas

Vertex Pharmaceuticals 4Q Rev $2.91B >VRTX

2025. g. 10. febr. 21:01 UTC

Peļņas

Vertex Pharmaceuticals 4Q Net $913M >VRTX

2025. g. 10. febr. 21:01 UTC

Peļņas

Vertex Pharmaceuticals 4Q Adj EPS $3.98 >VRTX

2025. g. 10. febr. 21:01 UTC

Peļņas

Vertex Pharmaceuticals 4Q EPS $3.50 >VRTX

2025. g. 31. janv. 09:59 UTC

Karstas akcijas

Stocks to Watch Friday: Intel, Apple, Vertex, Samsung -- WSJ

2024. g. 4. nov. 22:21 UTC

Peļņas

Vertex Beats Expectations, But Needs More To Drive 'Another Leg Of Stock Upside' -- IBD

2024. g. 4. nov. 21:25 UTC

Peļņas

Vertex Pharmaceuticals Beats Third-Quarter Estimates As Pain Treatment Looms -- IBD

2024. g. 4. nov. 21:03 UTC

Peļņas

Vertex Pharmaceuticals: Raising Full-Yr Pdt Rev Guidance to $10.8B to $10.9B >VRTX

Salīdzinājums

Cenas izmaiņa

Vertex Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

18.09% augšup

Prognoze 12 mēnešiem

Vidējais 512.95 USD  18.09%

Augstākais 621 USD

Zemākais 423 USD

Pamatojoties uz 26 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Vertex Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

26 ratings

14

Pirkt

12

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

428.545 / 498.65Atbalsts un pretestība

Īstermiņā

Very Strong Bearish Evidence

Vidējā termiņā

Weak Bearish Evidence

Ilgtermiņā

Bearish Evidence

Noskaņojums

By Acuity

314 / 382 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Lāču" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.